Phase I Trial of BAY1251152 for Advanced Blood Cancers

Status Completed

Clinical Trial Summary

The purpose of this study is to identify the most appropriate dose that can be safely administered and that can have an effect on blood cancer cells. Once that safe dose is identified, additional patients will be asked to join the study to further evaluate the safety and effectiveness of the study drug. The study will also investigate the pharmacokinetics (study of what the body does to the drug), as well as pharmacodynamics (study of what the drug does to the body), which may provide information about the effects of BAY 1251152. The study will also measure some biological markers (markers of biological activity in your body) that can be used to predict the response and safety of the proposed treatment.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Hematologic Neoplasms

Clinical Trial Details

NCT number	NCT02745743
Study type	Interventional
Source	Bayer
Contact
Status	Completed
Phase	Phase 1
Start date	June 17, 2016
Completion date	August 3, 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03483194` - Therapeutic Virtual Reality : Impact on the Management of Pain and Anxiety Related to Hematology Care (REVEH)	Phase 2/Phase 3
Recruiting	`NCT03735992` - Mind-body Medicine for Patients With Malignant Hematological Diseases	N/A
Recruiting	`NCT04959175` - Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies	Phase 1/Phase 2
Withdrawn	`NCT04275154` - Immunological Parameters, Neurocognitive Changes, Activity, & Driving Fitness in Patients Undergoing CAR-T Cell Therapy
Terminated	`NCT00957580` - Trial of Pimasertib in Hematological Malignancies	Phase 2
Completed	`NCT00997386` - Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States	Phase 2
Completed	`NCT00389428` - Multicenter Study of CPX-351(Cytarabine:Daunorubicin) Liposome Injection in Patients With Advanced Hematologic Cancer.	Phase 1
Completed	`NCT02193880` - Safety of Post-transplant Alpha-beta Depleted T-cell Infusion Following Haploidentical Stem Cell Transplant (Haplo SCT)	N/A
Recruiting	`NCT00071045` - Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members
Not yet recruiting	`NCT05054231` - Immunological Profile for Patients Treated With CAR-T Cells	N/A
Completed	`NCT02650791` - Platelet Transfusion Requirements in Hematopoietic Transplantation Pilot Study	Phase 3
Completed	`NCT01362179` - National Marrow Donor Program Long-Term Donor Follow-Up
Terminated	`NCT02900248` - CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
Terminated	`NCT03648372` - A Study of TAK-981 in People With Advanced Solid Tumors or Cancers in the Immune System	Phase 1/Phase 2
Recruiting	`NCT03320915` - Efficacy and Safety of High Dose Vitamin D Supplementation in Patients Undergoing HSCT	Phase 2
Recruiting	`NCT06422533` - Ceftolozane/Tazobactam vs. Piperacillin/Tazobactam for the Treatment of Bacteremia in Hemato-oncological Patients	N/A
Terminated	`NCT02895529` - A Study Comparing the Efficacy of Intravenous Followed by Oral Itraconazole With Intravenous Caspofungin For Empiric Antifungal Therapy in Neutropenic Participants With Hematological Malignancy	Phase 4
Active, not recruiting	`NCT03680092` - Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation	Phase 2
Recruiting	`NCT03083327` - Prophylactic Early PN in HPT/BMT	N/A
Recruiting	`NCT03743480` - Early Palliative Care and Hematological Cancer Patients	N/A